<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SUMMARY: Esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> continues to rise in incidence </plain></SENT>
<SENT sid="1" pm="."><plain>Despite recognition of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> as the histological precursor, prognosis remains poor </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinases (MAPK) pathway is activated in Barrett's-associated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and this activation is, in part, due to acid and <z:chebi fb="0" ids="3098">bile acid</z:chebi> reflux </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the effects of <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, an orally active Raf-inhibitor, on acid and <z:chebi fb="0" ids="3098">bile acid</z:chebi>-stimulated growth and signaling in SEG-1 cells, derived from a Barrett's <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>SEG-1 cells were pretreated with <z:chebi fb="0" ids="50924">sorafenib</z:chebi> or vehicle and subsequently stimulated with acid or <z:chebi fb="0" ids="3098">bile acid</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>MAPK signals, including phospho-ERK and phospho-p38, as well as cyclin D1 expression were assessed by Western blotting </plain></SENT>
<SENT sid="6" pm="."><plain>Cell proliferation was measured by WST-1 colorimetric assay </plain></SENT>
<SENT sid="7" pm="."><plain>Acid (pH 3.0-4.0) and <z:chebi fb="0" ids="3098">bile acid</z:chebi> (<z:chebi fb="0" ids="36257">taurocholate</z:chebi> 50-100 micromol/L) activated ERK and p38 </plain></SENT>
<SENT sid="8" pm="."><plain>Acid and <z:chebi fb="0" ids="3098">bile acid</z:chebi> exposure also increased levels of cyclin D1, a G1 to S cell cycle regulator </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, acid and <z:chebi fb="0" ids="36257">taurocholate</z:chebi> exposure <z:mp ids='MP_0000351'>increased cell proliferation</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="50924">Sorafenib</z:chebi> abrogated MAPK activation and cyclin D1 up-regulation and significantly inhibited cell growth </plain></SENT>
<SENT sid="11" pm="."><plain>In summary, <z:chebi fb="0" ids="50924">sorafenib</z:chebi> inhibits acid or <z:chebi fb="0" ids="3098">bile acid</z:chebi>-stimulated Barrett's <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> cell proliferation by a mechanism involving the MAPK pathway </plain></SENT>
<SENT sid="12" pm="."><plain>Our results suggest that <z:chebi fb="0" ids="50924">sorafenib</z:chebi> might be useful in the management of Barrett's-associated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>These findings provide a foundation for in vivo studies to assess the efficacy of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> in Barrett's-related <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
</text></document>